ArticleActa neuropathologica communications2025

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.

Yilamujiang Ainiwan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.